Research & University News

Embryo edits solve some problems, unleash new ones

An experiment in which CRISPR-Cas9 was used to repair a gene mutation in a human embryo appears to have solved two safety problems associated with this technology while raising ethical questions about its long-term application.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

UK medical charity benefits from Keytruda

A UK medical charity has decided that royalty income from intellectual property that it licensed to the developers of Keytruda, should be reinvested in innovation. The charity, LifeArc, has therefore set up two new funds to support academic research and early-stage biotech companies.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

UK scientists link pneumonia to unstable genes

Scientists at Imperial College London have determined that pneumococcal bacteria have been able to thwart vaccines because a “hotspot” of rapidly evolving

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Meeting Report – Liquid Biopsy

The term biopsy has traditionally been associated with the examination of tissue from a patient in order to detect the presence of disease. Tissue samples can be taken from the bone marrow, or organs such as the bladder, lung or liver, using procedures of varying complexity from the insertion of a needle into the skin, to surgery.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany

Mouse tumours killed with mRNA technology

For the first time, scientists at BioNTech AG have shown that it is possible to instruct an organism to create its own bispecific antibodies capable targeting and killing cancer. The experiment, conducted in mice, was reported in Nature Medicine on 12 June.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany

Heptares describes peptide hormone

Heptares Therapeutics has described the structure of the glucagon-like peptide-1 (GLP-1) receptor binding to a peptide agonist, giving the first visual evidence of how a class of drugs that treat Type 2 diabetes actually work. The findings were reported online in Nature on 31 May 2017.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Hookipa vaccine platform triggers response

A novel vaccine platform developed by Hookipa Biotech AG has triggered an immune response in genetically engineered mice with cancer that was stronger than many conventional viral vectors. The findings were published on 26 May 2017 in Nature Communications.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Austria

EMA reaches out to academia

The European Medicines Agency EMA) has formalised its ongoing relationship with universities in order to tap into research that could lead to new medicines and provide regulatory guidance to academic entrepreneurs.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Parkinson’s disease linked to gut bacteria

While most efforts at treating Parkinson’s disease have involved brain research, scientists from the California Institute of Technology (Caltech) have now shown in experiments with mice that bacteria in the gut may be releasing chemicals that over-activate parts of the brain leading to the disease.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Genome sequenced using hand-held device

UK researchers have reported sequencing the whole genomes of a human donor and a patient using a hand-held device based on nanopore technology. The device was developed by Oxford Nanopore Technologies Ltd, a venture capital-backed company based in Oxford UK.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Syndicate content